LGALS3BP and melanoma: A complementary study from the same research group measured the serum levels of LGALS3BP in 117 melanoma patients stratified into four risk group based on the stage of the disease, and it was confirmed that LGALS3BP may serve as a prognostic marker for clinical outcome in melanoma patients treated with immunotherapy [34].